Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice

Infection and Immunity

Volumn 75, Issue 4, 2007, Pages 1643-1650

  Tian, Haijun ^a   Groner, Avi ^a   Boes, Marianne ^b   Pirofski, Liise Anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG EFFICACY; IMMUNE DEFICIENCY; IMMUNOGENICITY; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPING; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, CD4; ANTIGENS, CD8; DISEASE MODELS, ANIMAL; IMMUNIZATION, PASSIVE; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 34147178159     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.01371-06     Document Type: Article

References (89)

1. H3 gene segment usage. J. Infect. Dis. 178:707-716.
2. Abzug, M. J., S. I. Pelton, L. Y. Song, T. Fenton, M. J. Levin, S. A. Nachman, W. Borkowsky, H. M. Rosenblatt, J. F. Marcinak, A. Dieudonne, E. J. Abrams, and I. Pathak. 2006. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr. Infect. Dis. J. 25:920-929.
3. Anttila, M., M. Voutilainen, V. Jantti, J. Eskola, and H. Kayhty. 1999. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin. Exp. Immunol. 118:402-407.
4. Artz, A. S., W. B. Ershler, and D. L. Longo. 2003. Pneumococcal vaccination and revaccination of older adults. Clin. Microbiol. Rev. 16:308-318.
5. -/- mice. Thymic positive selection is biased toward the helper phenotype. J. Immunol. 155:3727-3733.
6. Baker, P. J. 1992. T cell regulation of the antibody response to bacterial polysaccharide antigens: an examination of some general characteristics and their implications. J. Infect. Dis. 165(Suppl. 1):S44-S48.
7. Bartlett, J. G., S. F. Dowell, L. A. Mandell, J. T. M. File, D. M. Musher, and M. J. Fine. 2000. Practice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 31:347-382.
8. Boes, M., C. Esau, M. B. Fischer, T. Schmidt, M. Carroll, and J. Chen. 1998. Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. J. Immunol. 160:4776-4787.
9. Bogaert, D., M. Sluijter, R. de Groot, and P. W. Hermans. 2004. Multiplex opsonophagocytosis assay (MOPA): a useful tool for the monitoring of the 7-valent pneumococcal conjugate vaccine. Vaccine 22:4014-4020.
10. Briles, D. E., C. Forman, and M. Grain. 1992. Mouse antibody to phosphorylcholine can protect mice from infection with mouse-virulent human isolates of Streptococcus pneumoniae. Infect. Immun. 60:1957-1962.
11. Buchwald, U. K., A. Lees, M. Steinitz, and L. Pirofski. 2005. A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice. Infect. Immun. 73:333.
12. Buchwald, V. K., and L. Pirofski. 2003. Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. Curr. Pharm. Des. 9:945-968.
13. Butler, J. C., R. F. Breiman, J. F. Campbell, H. B. Lipman, C. V. Broome, and R. R. Facklam. 1993. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 270:1826-1831.
14. Casadevall, A., and L. A. Pirofski. 2004. New concepts in antibody-mediated immunity. Infect. Immun. 72:6191-6196.
15. Casadevall, A., and M. D. Scharff. 1994. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob. Agents Chemotherap. 38:1695-1702.
16. Centers for Disease Control and Prevention. 1997. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. 46:1-24.
17. Centers for Disease Control and Prevention. 2000. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. 49:1-35.
18. Centers for Disease Control and Prevention. 2005. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. Morb. Mortal. Wkly. Rep. 54:893-897.
19. Chan, C. Y., D. C. Molrine, S. George, N. J. Tarbell, P. Mauch, L. Diller, R. C. Shamberger, N. R. Phillips, A. Goorin, and D. M. Ambrosino. 1996. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J. Infect. Dis. 173:256-258.
20. Chang, Q., Z. Zhong, A. Lees, M. Pekna, and L. Pirofski. 2002. Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin loci. Infect. Immun. 70:4977-4986.
21. Concepcion, N., and C. E. Frasch. 1998. Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization. Clin. Diagn. Lab. Immunol. 5:199-204.
22. Cornu, C., D. Yzebe, P. Leophonte, J. Gaillat, J. P. Boissel, and M. Cucherat. 2001. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 19:4780-4790.
23. Dear, K., J. Holden, R. Andrews, and D. Tatham. 2003. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. CD000422.
24. Dorner, T., H. P. Brezinschek, S. J. Foster, R. I. Brezinschek, N. L. Farner, and P. E. Lipsky. 1998. Delineation of selective influences shaping the mutated and expressed human Ig heavy chain repertoire. J. Immunol. 160: 2831-2841.
25. Edwards, K. M., and M. R. Griffin. 2003. Great expectations for a new vaccine. N. Engl. J. Med. 349:1312-1314.
26. Fedson, D. S., and C. Liss. 2004. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 22:927-946.
27. File, T. M. 2003. Community-acquired pneumonia. Lancet 362:1991-2001.
28. Fine, D. P., J. L. Kirk, G. Schiffman, J. E. Schwinle, and J. C. Guckinan. 1988. Analysis of humoral and phagocytic defenses against Streptococcus pneumoniae serotypes 1 and 3. J. Lab. Clin. Med. 112:487-497.
29. Fung-Leung, W. P., M. W. Schilham, A. Rahemtulla, T. M. Kundig, M. Vollenweider, J. Potter, E. W. van, and T. W. Mak. 1991. CD8 is needed for development of cytotoxic T cells but not helper T cells. Cell 65:443-449.
30. Garcia-Ojeda, P. A., M. E. Monser, L. J. Rubinstein, H. J. Jennings, and K. E. Stein. 2000. Murine immune response to Neisseria meningitidis group C capsular polysaccharide: analysis of monoclonal antibodies generated in response to a thymus-independent antigen and a thymus-dependent conjugate vaccine. Infect. Immun. 68:239-246.
31. Heffron, R., B. White, and R. Austin. 1979. The biology of pneumococcus. Harvard University Press, Cambridge, MA.
32. Hu, B. T., X. Yu, T. R. Jones, C. Kirch, S. Harris, S. W. Hildreth, D. V. Madore, and S. A. Quataert. 2005. Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae. Clin. Diagn. Lab. Immunol. 12: 287-295.
33. Huo, Z., J. Miles, T. Harris, and P. Riches. 2002. Effect of Pneumovax II vaccination in high-risk individuals on specific antibody and opsonic capacity against specific and non-specific antigen. Vaccine 20:3532-3534.
34. Hutchison, B. G., A. D. Oxman, H. S. Shannon, S. Lloyd, C. A. Altmayer, and K. Thomas. 1999. Clinical effectiveness of pneumococcal vaccine. Meta-analysis. Can. Fam. Physician 45:2381-2393.
35. Jackson, L. A., K. M. Neuzil, O. yu, P. Benson, W. E. Barlow, A. L. Adams, C. A. Hanson, L. D. Mahoney, D. K. Shay, W. W. Thompson, and the Vaccine Study Datalink. 2003. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N. Engl. J. Med. 348:1755.
36. Jeurissen, A., M. Wuyts, A. Kasran, S. Ramdien-Murli, L. Boon, J. L. Ceuppens, and X. Bossuyt. 2002. Essential role for CD40 ligand interactions in T lymphocyte-mediated modulation of the murine immune response to pneumococcal capsular polysaccharides. J. Immunol. 168:2773-2781.
37. Kadioglu, A., and P. W. Andrew. 2004. The innate immune response to pneumococcal lung infection: the untold story. Trends Immunol. 25:143-149.
38. Kamboj, K. K., H. L. Kirchner, R. Kimmel, N. S. Greenspan, and J. R. Schreiber. 2003. Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein. J. Infect. Dis. 187:1629-1638.
39. Kroon, F. P., J. T. van Dissel, E. Ravensbergen, P. H. Nibbering, and R. van Furth. 1999. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine 18:524-530.
40. Lawrence, C. W., R. M. Ream, and T. J. Braciale. 2005. Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J. Immunol. 174:5332-5340.
41. Lefeber, D. J., B. Benaissa-Trouw, J. F. Vliegenthart, J. P. Kamerling, W. T. Jansen, K. Kraaijeveld, and H. Snippe. 2003. Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3. Infect. Immun. 71:6915-6920.
42. Lindell, D. M., T. A. Moore, R. A. McDonald, G. B. Toews, and G. B. Huffnagle. 2005. Generation of antifungal effector CD8+ T cells in the absence of CD4+ T cells during Cryptococcus neoformans infection. J. Immunol. 174:7920-7928.
43. Madhi, S. A., E. Cumin, and K. P. Klugman. 2002. Defining the potential impact of conjugate bacterial polysaccharide-protein vaccines in reducing the burden of pneumonia in human immunodeficiency virus type 1-infected and -uninfected children. Pediatr. Infect. Dis. J. 21:393-399.
44. Madsen, L., N. Labrecque, J. Engberg, A. Dierich, A. Svejgaard, C. Benoist, D. Mathis, and L. Fugger. 1999. Mice lacking all conventional MHC class II genes. Proc. Natl. Acad. Sci. USA 96:10338-10343.
45. Makela, O., P. Mattila, N. Rautonen, I. Seppala, J. Eskola, and H. Kayhty. 1987. Isotype concentrations of human antibodies to Haemophilus influenzae type b polysaccharide (Hib) in young adults immunized with the polysaccharide as such or conjugated to a protein (diphtheria toxoid). J. Immunol. 139:1999-2004.
46. Mangtani, P., F. Cutts, and A. J. Hall. 2003. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect. Dis. 3:71-78.
47. Marrie, T. J. 1999. Pneumococcal pneumonia: epidemiology and clinical features. Semin. Respir. Infect. 14:227-235.
48. Martinez, J. E., E. A. Clutterbuck, H. Li, S. Romero-Steiner, and G. M. Carlone. 2006. Evaluation of multiplex flow cytometric opsonophagocytic assays for determination of functional anticapsular antibodies to Streptococcus pneumoniae. Clin. Vaccine Immunol. 13:459-466.
49. McCool, T. L., C. V. Harding, N. S. Greenspan, and J. R. Schreiber. 1999. B-and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity. Infect. Immun. 67:4862-4869.
50. McLay, J., E. Leonard, S. Petersen, D. Shapiro, N. S. Greenspan, and J. R. Schreiber. 2002. Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides. II. Increased susceptibility to fatal pneumococcal sepsis due to absence of anti-polysaccharide IgG3 is corrected by induction of anti-polysaccharide IgG1. J. Immunol. 168:3437-3443.
51. Miiro, G., H. Kayhty, C. Watera, H. Tolmie, J. A. Whitworth, C. F. Gilks, and N. French. 2005. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J. Infect. Dis. 192:1801-1805.
52. Moore, R. A., P. J. Wiffen, and B. A. Lipsky. 2000. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam. Pract. 1:1.
53. Moore, T. A., M. L. Perry, A. G. Getsoian, M. W. Newstead, and T. J. Standiford. 2002. Divergent role of gamma interferon in a murine model of pulmonary versus systemic Klebsiella pneumoniae infection. Infect. Immun. 70:6310-6318.
54. Morgado, M. G., P. Cam, C. Gris-Liebe, P. A. Cazenave, and E. Jouvin-Marche. 1989. Further evidence that BALB/c and C57BL/6 gamma 2a genes originate from two distinct isotypes. EMBO J. 8:3245-3251.
55. Musher, D. M., J. E. Groover, D. A. Watson, M. C. Rodriguez-Barradas, and R. E. Baughn. 1998. IgG responses to protein-conjugated pneumococcal capsular polysaccharides in persons who are genetically incapable of responding to unconjugated polysaccharides. Clin. Infect. Dis. 27:1487-1490.
56. Nahm, M. H., J. V. Olander, and M. Magyarlaki. 1997. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae. J. Infect. Dis. 176:698-703.
57. Neff-LaFord, H. D., B. A. Vorderstrasse, and B. P. Lawrence. 2003. Fewer CTL, not enhanced NK cells, are sufficient for viral clearance from the lungs of immunocompromised mice. Cell. Immunol. 226:54-64.
58. Netski, D., and T. R. Kozel. 2002. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity. Infect. Immun. 70:2812-2819.
59. Nielsen, H., B. Kvinesdal, T. L. Benfield, J. D. Lundgren, and H. B. Konradsen. 1998. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Scand. J. Infect. Dis. 30:597-601.
60. Perlmutter, R. M., D. Hansburg, D. E. Briles, R. A. Nicolotti, and J. M. Davie. 1978. Subclass restriction of murine anti-carbohydrate antibodies. J. Immunol. 121:566-572.
61. Pinchuk, I., B. C. Starcher, B. Livingston, A. Tvninnereim, S. Wu, E. Appella, J. Sidney, A. Sette, and B. Wizel. 2005. A CD8+ T cell heptaepitope minigene vaccine induces protective immunity against Chlamydia pneumoniae. J. Immunol. 174:5729-5739.
62. Pirofski, L., and A. Casadevall. 1998. The use of licensed vaccines for active immunization of the immunocompromised host. Clin. Microbiol. Rev. 11:1-26.
63. Poland, G. A. 1999. The burden of pneumococcal disease: the role of conjugate vaccines. Vaccine 17:1674-1679.
64. Puumalainen, T., N. Ekstrom, R. Zeta-Capeding, J. Ollgren, K. Jousimies, M. Lucero, H. Nohynek, and H. Kayhty. 2003. Functional antibodies elicited by an 11-valent diphtheria-tetanus toxoid-conjugated pneumococcal vaccine. J. Infect. Dis. 187:1704-1708.
65. Rahemtulla, A., W. P. Fung-Leung, M. W. Schilham, T. M. Kundig, S. R. Sambhara, A. Narendran, A. Arabian, A. Wakeham, C. J. Paige, R. M. Zinkernagel, et al. 1991. Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature 353:180-184.
66. Rahemtulla, A., A. Shahinian, T. Kundig, R. Zinkernagel, and T. W. Mak. 1993. CD4 negative mice as a model for immunodeficiency. Philos. Trans. R. Soc. London B 342:57-58.
67. Ren, B., A. J. Szalai, S. K. Hollingshead, and D. E. Briles. 2004. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect. Immun. 72:114-122.
68. Robbins, J. B., R. Schneerson, and S. C. Szu. 1995. Hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171:1387-1398.
69. Rodriguez-Barradas, M. C., I. Alexandras, T. Nazir, M. Foltzer, D. M. Musher, S. Brown, and J. Thornby. 2003. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin. Infect. Dis. 37:438-447.
70. Romero-Steiner, S., C. E. Frasch, G. Cartone, R. A. Fleck, D. Goldblatt, and M. H. Nahm. 2006. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin. Vaccine Immunol. 13:165-169.
71. Romero-Steiner, S., D. Libutti, L. B. Pais, et al. 1997. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin. Diagn. Lab. Immunol. 4:415-422.
72. Rubins, J. B., and C. Pomeroy. 1997. Role of gamma interferon in the pathogenesis of bacteremic pneumococcal pneumonia. Infect. Immun. 65: 2975-2977.
73. Rubinstein, L. J., P. A. Garcia-Ojeda, F. Michon, H. J. Jennings, and K. E. Stein. 1998. Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine. Infect. Immun. 66:5450-5456.
74. Russell, N., J. R. Corvalan, M. L. Gallo, C. G. Davis, and L. Pirofski. 2000. Production of protective human antipneumococcal antibodies by transgenic mice with human immunoglobulin loci. Infect. Immun. 68:1820-1826.
75. Sable, S. B., S. Kaur, I. Verma, and G. K. Khuller. 2005. Immunodominance of low molecular weight secretory polypeptides of Mycobacterium tuberculosis to induce cytotoxic T-lymphocyte response. Vaccine 23:4947-4954.
76. Shapiro, D. A., D. S. Threadgill, M. J. Copfer, D. A. Corey, T. L. McCool, L. L. McCormick, T. R. Magnuson, N. S. Greenspan, and J. R. Schreiber. 1998. Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides undergo normal isotype switching after immunization with polysaccharide-protein conjugate vaccines. J. Immunol. 161:3393-3399.
77. + T cells in control of West Nile virus infection. J. Virol. 78:8312-8321.
78. Smit, P., D. Oberbolzer, S. Hayden-Smith, H. J. Koornhof, and M. R. Hilleman. 1977. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 238:2613-2616.
79. Soininen, A., M. Karpala, S. L. Wahlman, H. Lehtonen, and H. Kayhty. 2002. Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children. Clin. Diagn. Lab. Immunol. 9:1032-1038.
80. Sorensen, R. U., L. E. Leiva, P. A. Giangrosso, B. Butler, F. C. Javier III, D. M. Sacerdote, N. Bradford, and C. Moore. 1998. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr. Infect. Dis. J. 17:685-691.
81. Subramaniam, K. S., R. Segal, R. H. Lyles, M. C. Rodriguez-Barradas, and L. A. Pirofski. 2003. Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy. J. Infect. Dis. 187:768.
82. Thornton, J., and L. S. McDaniel. 2005. THP-1 monocytes up-regulate intercellular adhesion molecule 1 in response to pneumolysin from Streptococcus pneumoniae. Infect. Immun. 73:6493-6498.
83. Vakevainen, M., W. Jansen, E. Saeland, I. Jonsdottir, H. Snippe, A. Verheul, and H. Kayhty. 2001. Are the opsonophagocytic activities of antibodies in infant sera measured by different pneumococcal phagocytosis assays comparable? Clin. Diagn. Lab. Immunol. 8:363-369.
84. Warfield, K. L., G. Olinger, E. M. Deal, D. L. Swenson, M. Bailey, D. L. Negley, M. K. Hart, and S. Bavari. 2005. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J. Immunol. 175:1184-1191.
85. Watson, L., B. J. Wilson, and N. Waugh. 2002. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 20: 2166-2173.
86. Wuthrich, M., T. Filutowicz, T. Warner, G. S. Deepe, and B. S. Klein. 2003. Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. J. Exp. Med. 197:1405-1416.
87. Yuan, R., A. Casadevall, and M. D. Scharff. 1997. T cells cooperate with passive antibody to modify the course of Cryptococcus neoformans in mice. Proc. Natl. Acad. Sci. USA 94:2483-2488.
88. Zhong, Z., T. Burns, Q. Chang, M. Carroll, and L. Pirofski. 1999. Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide. Infect. Immun. 67:4119-4127.
89. Zhong, Z., and L. Pirofski. 1996. Opsonization of Cryptococcus neoformans by human antiglucuronoxylomannan antibodies. Infect. Immun. 64:3446-3450.